
Opinion|Videos|July 29, 2024
Beyond EHA 2024: Promising Research in Multiple Myeloma to Watch
Author(s)Joseph Mikhael, MD
Dr. Mikhael discusses EHA 2024 data he found particularly noteworthy to share with colleagues.
Advertisement
Episodes in this series

Video content above is prompted by the following question:
- Please discuss any other data in multiple myeloma released at EHA 2024 that you find noteworthy to share with colleagues.
- Outside of EHA 2024 what ongoing research efforts are you most excited for in the treatment and management of multiple myeloma?
- What can we look forward to through the end of the year and beyond?
Advertisement
Related to this article

Real-world acne treatment adherence spans 6% to 84%, with cost, adverse effects, and slow results driving nonadherence.

A value-based care pilot within Kentucky’s Medicaid program reduced total costs for adults with substance use disorder while improving utilization of evidence-based treatments.

A scalable, symptom-focused patient education model paired with coordinated podiatric care offers managed care organizations a low-barrier strategy to reduce diabetic foot ulcers and costly amputations.

Pimicotinib, a once-daily oral CSF-1R inhibitor, is now FDA approved for adults with TGCT for whom surgery may worsen function or cause severe morbidity.

Pooled real-world data show an 88% response rate with brexu-cel in relapsed mantle cell lymphoma (MCL), but cost and QOL data are scarce.

Employer diabetes guide; Camden psychedelic therapy input; CRC after EMR; rural HFrEF care; JAMA obesity report.

This article analyzes gaps in US biosimilar development, quantifies market opportunities, and proposes policy and economic solutions to improve cost savings and patient access.
Advertisement
Advertisement
Trending on AJMC
1
Health Equity & Access Weekly Roundup: November 20, 2026
2
Defining High-Efficacy MS Therapy: Access, Formularies, and Patient Choice
3
FDA Approves Pimicotinib for Symptomatic Tenosynovial Giant Cell Tumor
4
FDA Approves Dexmedetomidine Sublingual Film as At-Home Agitation Therapy
5

